Novel agent submissions took center stage in the past week, thanks to applications for Sanofi and Regeneron Pharmaceuticals Inc.'s dupilumab for atopic dermatitis, an indication that has already received a breakthrough therapy designation, and Biogen Inc. and Ionis Pharmaceuticals Inc.'s nusinersen, which could be the first drug to treat spinal muscular atrophy. Here's your news in brief:
AbbVie Inc. submitted a supplemental new drug application (sNDA) for a new indication for Imbruvica for treatment of marginal...




